Genetic Panel Selection for Renal Denervation in Resistant Hypertension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current renal denervation procedures for treating hypertension, particularly resistant hypertension, have variable success rates due to individual patient responses, with many patients not experiencing significant blood pressure reductions, and there is a need for methods to identify patients likely to benefit from these treatments.
Innovation Solution
A genetic panel analysis is conducted to identify specific genetic variants in the sympathetic nervous system, cardiac, vascular, and renal systems to predict patient responsiveness to renal denervation procedures, guiding tailored denervation treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If renal denervation procedures are performed on all hypertensive patients, then some patients may achieve blood pressure control, but many patients will not experience significant blood pressure reductions due to variable individual responses
Solution Approach 1:
The patent applies preliminary action by conducting genetic panel analysis before renal denervation procedures to identify patients with specific genetic variants (ADRB1, ADRB2, ADRA2A, ADRA2C) who are likely to respond positively to the treatment. This pre-screening approach allows clinicians to select appropriate candidates beforehand, avoiding ineffective procedures on patients unlikely to benefit.
Solution Approach 2:
The patent utilizes parameter changes by analyzing genetic parameters (DNA sequences and variants) to predict treatment response. By examining specific genetic markers and their variations among individuals, the method identifies patterns that correlate with successful blood pressure control following renal denervation, thereby changing the approach from universal treatment to targeted therapy based on genetic parameters.
2Reliability
If genetic panel analysis is conducted to identify responsive patients, then treatment success rate increases, but the complexity of the treatment process increases due to additional testing requirements
Solution Approach 1:
The patent applies segmentation by dividing the genetic analysis into specific, discrete components - testing for particular genes (ADRB1, ADRB2, ADRA2A, ADRA2C) and their specific variants rather than conducting comprehensive genomic sequencing. This segmented approach focuses on the most clinically relevant genetic markers, simplifying the overall testing process while maintaining predictive accuracy.
Solution Approach 2:
The patent changes the approach from complex, comprehensive genetic profiling to analyzing specific, predefined genetic parameters and markers. By focusing on known variants associated with blood pressure regulation and renal denervation response, the method reduces analytical complexity while preserving the ability to predict treatment outcomes accurately.
Data Source
AI summary
The present invention concerns selective renal denervation treatment of drug resistant hypertensive patients by correlating the patients' genetic panel by categorization and hierarchy according to patients' genetic variants within the functional genes for heart activity, for the renin-angiotensin aldosterone system, and for renal activity.